2Lindholm A,Kahan BD.Inf luence of cyclosporine pharmacokinetics,trough concentrations and AUC monitorin g on outcome after kidney transplantation[J].Clin Pharmacol Ther,1993,54(2) : 205-218.
3Kahan BD,Welsh M,Schoenberg L,et al.Variable ora l absorption of cyclosporine.A biopharmaceutical risk factor for chronic renal allograft rejection[J].Transplantation,1996,62(5): 599-606.
4Mahalati K,Belitsky P,Sketris I,et al.Neoral monitoring by simplified spar se sampling area under the concentration-time curve: its relationship to acute r ejection and cyclosporine nephrotoxicity early after kidney transplan tation[J].Transplantation,1999,68(1): 55-62.
5John ston A,David OJ,Cooney GF.Pharmacokinetic validation of neoral absorption pro filing[J].Transplant Proc,2000,32(suppl 3A): 53s-56s.
6Gran t D,Kneteman N,Tchervenkov J,et al.Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection[J].Transplantation,1999,67(8): 113 3-1137.
7Halloran PF,Helms LM,Kung L,et al.The temporal prof ile of calcineurin inhibition by cyclosporine in vivo[J].Transplantation,199 9,68(9): 1356-1361.
8Levy GA,Lake JR,Beauregard-Zollinger L,et al.Improved clinical outcomes for liver transplant recipients using cyclaspo rine blood level monitoring based on two-hour post-dose levels[J].Transplanta tion,2000,69(8): s387,abstract 1059.
